Brian Reed: Hey. Good to be here.
Eliza Ward: Yeah, good — I've been sitting with something all morning, actually.
Brian Reed: The Bayer thing?
Eliza Ward: The Bayer thing. FDA approved Sunharbo — asundexian — early November. First-in-class, once-daily pill for secondary stroke prevention.
Brian Reed: And the headline number out of OCEANIC-STROKE is twenty-six percent reduction in recurrent ischemic stroke risk. Which — hang on — that's versus placebo, right? Not versus what people are already taking.
Eliza Ward: Correct. Placebo. Twelve thousand, three hundred twenty-seven patients, median follow-up fourteen-point-two months — everyone's on antiplatelet therapy on top of it.
Brian Reed: So the question that immediately opens up for me is — if the trial never ran it head-to-head against clopidogrel-aspirin, what does the approval actually tell a neurologist about which drug to reach for?
Eliza Ward: That's exactly the gap. And it's approved for non-cardioembolic ischemic stroke and high-risk TIA — specifically not atrial fibrillation. So the population is defined, the bar it had to clear was placebo, and the FDA fast track got it here faster. Whether that's enough for clinical adoption is a different sentence entirely.
Brian Reed: But even that framing — 'twenty-six percent better than placebo' — I want to slow that down because every single one of those twelve thousand patients was already on antiplatelet therapy. So the placebo arm isn't people with no protection. It's people with one lock on the door. Sunharbo is the second lock.
Eliza Ward: That's exactly the right frame. The twenty-six percent is what the second lock adds — not how much safer you are than someone with no locks at all.
Brian Reed: Which means the absolute number becomes everything. Because if the first lock is already doing most of the work—
Eliza Ward: Right — and here's the problem. The absolute risk reduction isn't publicly disclosed. We don't have it from the available sources. So we can't say how many stroke survivors have to take Sunharbo for a year to prevent one repeat stroke. That number just... isn't out there yet.
Brian Reed: Wait, the number-needed-to-treat isn't published?
Eliza Ward: Not in what's available, no. And that matters because — I mean, the CHANCE trial showed a thirty-two percent stroke reduction with clopidogrel-aspirin, which is the existing dual antiplatelet standard, and we do have those absolute figures. With Sunharbo we're comparing a relative headline to a gap.
Brian Reed: So the coverage is leading with the relative number — which is real, I want to be clear, twenty-six percent isn't fabricated — but without the absolute figure, an individual patient can't actually weigh this. The percentage is real, the translation to 'what does this mean for me' is just... missing.
Eliza Ward: That's the signal-versus-hype line. The trial result is confirmed. What we can't do yet is hand it to a patient and say here's your personal risk math. Those are different sentences.
Brian Reed: And that gap — the missing absolute number — is actually what breaks the take I keep seeing, which is that this approval proves Sunharbo is better than what neurologists are already doing.
Eliza Ward: Wait, say that more precisely. Better how?
Brian Reed: Better than clopidogrel-aspirin. Dual antiplatelet. The thing that's already in the guideline. Because the OCEANIC-STROKE trial never ran against it — it ran against placebo — and the CHANCE trial, which did test clopidogrel-aspirin for minor stroke and TIA, showed a thirty-two percent stroke reduction. That's numerically higher than Sunharbo's twenty-six.
Eliza Ward: Not a direct comparison.
Brian Reed: No, different trials, different designs — I want to be clear about that. But a payer or formulary committee looking at this has to ask: why favor a branded drug when the generic combination has a higher number in a similar population and we have the POINT trial confirming it too? The head-to-head that would actually answer the question doesn't exist.
Eliza Ward: And Sunharbo isn't even replacing antiplatelet therapy — it's approved to layer on top of it. So the clinical question isn't either-or, it's whether adding a factor XIa inhibitor on top of what someone's already taking is worth it. Which, again, we don't have head-to-head data for.
Brian Reed: That's — yeah, that reframes it entirely. It's not 'Sunharbo versus clopidogrel,' it's 'clopidogrel-plus-Sunharbo versus clopidogrel alone,' and that trial just wasn't run.
Eliza Ward: And there's another hard boundary people are skipping — it's not approved for atrial fibrillation patients. That's explicitly outside the label. So anyone reading 'stroke prevention' and assuming this is broad — it isn't. Non-cardioembolic only.
Brian Reed: The piece that I think is going to matter most comes later — what happens when this hits real-world patients, older, more medicated, and what payers actually do without that head-to-head data to justify the switch.
Eliza Ward: And that's exactly where I want to put a person in that room, because it stops being abstract fast. Picture a 76-year-old — just had a mild ischemic stroke, non-cardioembolic, so she's squarely in the approved population. She's already on aspirin, already on a statin. Her neurologist in a community hospital is looking at Sunharbo on the shelf, no head-to-head data against clopidogrel, and — wait, here's the part that hasn't come up yet — no published price, no formulary decision. She literally cannot know what this costs.
Brian Reed: And she's eight years older than the median trial patient.
Eliza Ward: Right. OCEANIC-STROKE median age was 68. So the safety profile we have — no increase in ISTH major bleeding versus placebo, which is genuinely encouraging — that's from a population that skews younger and was screened for the trial. She wasn't in that trial.
Brian Reed: The part that gets me is the follow-up window. 14.2 months — that's just over a year. If she takes Sunharbo for three years, which is plausible for secondary prevention, what does bleeding risk look like in year two or three? We have no idea.
Eliza Ward: No data. That's a confirmed gap, not speculation. The factor XIa mechanism is theorized to spare normal hemostasis more than older anticoagulants — the biology is plausible — but plausible at a molecular level and validated across tens of thousands of real patients for three years are very different sentences.
Brian Reed: So what's the actual watching point? Like — what event tells us something we don't know now?
Eliza Ward: Three things, I think. Real-world adverse event reporting through FDA's post-market surveillance — that's where older, sicker patients actually show up. Second, pricing and formulary announcements from Bayer, because without those a formulary committee cannot rationally choose this over a cheap generic clopidogrel. And third — actually this is the one I'd watch hardest — whether anyone designs a comparative-effectiveness trial that runs Sunharbo directly against dual antiplatelet therapy. That trial doesn't exist. If it gets designed, that changes everything.
Brian Reed: And until that trial exists, the neurologist treating that 76-year-old is essentially — I mean, she's making a call in a vacuum. Good biology, clean phase 3 safety signal, unanswered price question, no head-to-head. That's the actual decision.
Eliza Ward: That's what the approval settled and what it didn't. The pharmacology is solved enough for FDA. The clinical adoption question is still open.
Brian Reed: And that's — I mean, that's what I keep thinking about. Regulatory approval is one gate. Genuinely one gate. But the second gate — will a formulary committee at a community hospital actually cover this, will a neurologist actually switch a patient who's already stable on clopidogrel — that gate is just... still closed. And the data that would open it doesn't exist yet.
Eliza Ward: Right — and Bayer has the first-in-class story, the FDA fast track, the November approval. That's real. The factor XIa mechanism is genuinely novel pharmacology. What it's not is proof of clinical superiority. Those aren't the same sentence.
Brian Reed: So what do we actually not know yet? Just — plainly.
Eliza Ward: Whether real-world prescribing patterns bear this out — that shows up in adverse-event reporting, older patients, people outside the OCEANIC-STROKE selection criteria. Bayer's pricing and formulary positioning, which we don't have. And, most importantly, whether anyone — Bayer or independent investigators — ever actually runs the comparative-effectiveness trial against dual antiplatelet therapy. That trial does not exist. That's the fact that would change the whole picture.
Brian Reed: Until then — good biology, one clean phase 3 signal, a lot of open questions. That's genuinely where this is.